Innovent Announces Phase 2 study of Mazdutide（IBI362） in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints

SAN FRANCISCO and SUZHOU, China, June 7, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic,...

Click to view original post